Research Papers:

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Ying Wang, Zhengsheng Zhan, Xifei Jiang, Xia Peng, Yanyan Shen, Fang Chen, Yinchun Ji, Weiren Liu, Yinghong Shi, Wenhu Duan, Jian Ding, Jing Ai _ and Meiyu Geng

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:38091-38104. https://doi.org/10.18632/oncotarget.9349

Metrics: PDF 1661 views  |   HTML 2033 views  |   ?  


Ying Wang1,*, Zhengsheng Zhan2,*, Xifei Jiang3,4,*, Xia Peng1, Yanyan Shen1, Fang Chen2, Yinchun Ji1, Weiren Liu3,4, Yinghong Shi3,4, Wenhu Duan2, Jian Ding1, Jing Ai1, Meiyu Geng1

1Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R.China

2Department of Medicinal Chemistry Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R.China

3Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P.R.China

4Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, P.R.China

*These authors have contributed equally to this work

Correspondence to:

Jing Ai, e-mail: [email protected]

Meiyu Geng, e-mail: [email protected]

Keywords: c-Met, kinase inhibitor, Simm530

Received: October 29, 2015     Accepted: April 29, 2016     Published: May 13, 2016


The aberrant c-Met activation has been implicated in a variety of human cancers for its critical role in tumor growth, metastasis and tumor angiogenesis. Thus, c-Met axis presents as an attractive therapeutic target. Notably, most of these c-Met inhibitors currently being evaluated in clinical trials lack selectivity and target multiple kinases, often accounting for the undesirable toxicities. Here we described Simm530 as a potent and selective c-Met inhibitor. Simm530 demonstrated >2,000 fold selectivity for c-Met compared with other 282 kinases, making it one of the most selective c-Met inhibitors described to date. This inhibitor significantly blocked c-Met signaling pathways regardless of mechanistic complexity implicated in c-Met activation. As a result, Simm530 led to substantial inhibition of c-Met-promoted cell proliferation, migration, invasion, ECM degradation, cell scattering and invasive growth. In addition, Simm530 inhibited primary human umbilical vascular endothelial cell (HUVEC) proliferation, decreased intratumoral CD31 expression and plasma pro-angiogenic factor interleukin-8 secretion, suggesting its significant anti-angiogenic properties. Simm530 resulted in dose-dependent inhibition of c-Met phosphorylation and tumor growth in c-Met-driven lung and gastric cancer xenografts. And, the inhibitor is well tolerated even at doses that achieve complete tumor regression. Together, Simm530 is a potent and highly selective c-Met kinase inhibitor that may have promising therapeutic potential in c-Met-driven cancer treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9349